CLARA D. BLOOMFIELD, M. D.
This content is PDF only. Please click on the PDF icon to access.
Impressive advances in the treatment of adult acute nonlymphocytic leukemia have occurred during the last 10 years. The percentage of patients achieving complete remission has increased. The median durations of these remissions have lengthened, and the percentage of longterm survivors has risen. Ten years ago, a 25% remission rate for adults was exceptional. Today complete remission rates of more than 50% are regularly achieved in large cooperative group trials (1,2), and using combinations that include an anthracycline antibiotic (daunorubicin hydrochloride or doxorubicin hydrochloride), cytarabine, and 6-thioguanine or 6-mercaptopurine, complete remission rates of more than 80% have been reported by several
BLOOMFIELD CD. Treatment of Adult Acute Nonlymphocytic Leukemia—1980. Ann Intern Med. ;93:133–135. doi: 10.7326/0003-4819-93-1-133
Download citation file:
Published: Ann Intern Med. 1980;93(1_Part_1):133-135.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use